Researchers
Statement of Beliefs
We have heard some say that Alzheimer’s disease is an inevitable part of aging. Others have claimed that it simply cannot be prevented or effectively treated anytime soon. Still others believe that we simply cannot afford to do what it would take to stop the disease. They are all wrong.
As men and women of science, we are united by a simple but bold belief: It is possible to prevent and effectively treat Alzheimer’s disease within our lifetimes, but only if our nation does what is necessary:
- Set an aggressive goal of stopping Alzheimer’s disease by 2025, because it will focus the energies of the research community;
- Invest significant resources in Alzheimer’s disease research and innovation, because our commitment to cures must match the scale of the challenge;
- Institute reforms to accelerate the drug pipeline and deliver therapies to patients faster, because the ultimate goal of research is to bring help to those afflicted, and to prevent the disease from afflicting future generations.
If government, private industry, and the research community unite with a common goal and purpose backed with the necessary leadership, resources and incentives, the power of scientific research can be unleashed to unlock new possibilities, to deliver new cures – and to prevent and treat Alzheimer’s disease.
The Founding Members of ResearchersAgainstAlzheimer's will approve any variations of this language and will distribute any approved additions or revisions to all signers upon use. Any approved variations will reflect a broad consensus of the research and scientific community.
Members of the network will be expected to:
- Add their name to the ResearchersAgainstAlzheimer’s statement of belief;
- Engage in an advocacy action (such as signing a letter to a policymaker, submitting an op-ed or Letter to the Editor, or being willing to meet with and educate policymakers) at least twice per year; and
- Be available to speak to the press on the need to increase Federal support for Alzheimer’s research and other policy interventions.
Founding Members
Paul Aisen, M.D.
Director, Alzheimer's Disease Cooperative StudyMarilyn Albert, Ph.D.
Director of the Division of Cognitive Neuroscience in the Department of Neurology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Alzheimer's Disease Research CenterDavid Bennett, M.D.
Robert C. Borwell Professor of Neurological Sciences and Director of the Rush Alzheimer's Disease CenterJeff Cummings, M.D.
Director of the Cleveland Clinic Lou Ruvo Center for Brain HealthSteve DeKosky, M.D.
Dean of the University of Virginia School of MedicineRachelle Doody, M.D., Ph.D.
Director, Alzheimer's Disease and Memory Disorder Center at Baylor College of Medicine Center
Howard Fillit, M.D.
Executive Director, Alzheimer's Drug Discovery FoundationDavid Holtzman, M.D.
Chair, Department of Neurology, Washington University, St. LouisBruce Lamb, Ph.D.
Staff Scientist, Department of Neurosciences,The Lerner Research Institute, The Cleveland Clinic FoundationDavid Morgan, Ph.D.
CEO, Byrd Alzheimer's Institute, University of South FloridaRon Petersen, M.D., Ph.D.
Director, Mayo Alzheimer's Disease Research Center
Reisa Sperling, M.D.
Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical SchoolRudy Tanzi, Ph.D.
Director, Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical SchoolJohn Trojanowski, M.D., Ph.D.
Co-Director, Center for Neurodegenerative Disease Research and Director of the Alzheimer's Disease Center of the University of PennsylvaniaMichael Weiner, M.D.
Director of the Center for Imaging of Neurodegenerative disease, San Francisco Veteran's Administration Medical Center and Professor of Medicine, Radiology, Psychiatry, and Neurology University of California, San Francisco
Affiliations are for identification purposes only and do not necessarily represent the endorsement of the affiliated institution.
Latest
Comments regarding the "Interim Milestones to Complete the First Goal of the National Alzheimer's Plan by 2025"May 13, 2013Click here to read the comments submitted on Friday, May 10 on the "Interim Milestones to Complete the First Goal of the National Alzheimer's Plan by 2025" that were included in the recommendations by the Advisory Council o |
Comments in support of FDA guidance on "Developing Drugs for the Treatment of Early Stage Disease"April 9, 2013Click here to read the full letter. |
Pressure Rising To Avoid Federal Spending Cuts That Will Impact Health ProgramsFebruary 20, 2013Pressure is mounting for Washington to find a way to avoid the automatic spending reductions set to begin March 1, with President Barack Obama Tuesday urging Congress to stop the "meat-cleaver approach" that he says will undermine U.S. military strength and "eviscerate job creating investments in education and energy and medical research." |
Action Center
SPREAD THE WORD
Tell your colleagues about ResearchersAgainstAlzheimer’s and ask them to join us. Together, our voices will be heard more forcefully than any one voice alone.
